The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-07 and is reviewed periodically as new material appears.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Twinlab Consolidated Corporation is an American company which manufactures and markets vitamins, minerals, and bodybuilding supplements. Twinlab is based in Boca Raton, Florida. Twinlab currently produces more than 500 different products.
The declaration represented the first public support for Zionism by a major political power – its publication galvanized Zionism, which finally had obtained an official charter. In addition to its publication in major newspapers, leaflets were circulated throughout Jewish communities. These leaflets were airdropped over Jewish communities in Germany and Austria, as well as the Pale of Settlement, which had been given to the Central Powers following the Russian withdrawal. Weizmann had argued that the declaration would have three effects: it would swing Russia to maintain pressure on Germany's Eastern Front, since Jews had been prominent in the March Revolution of 1917; it would rally the large Jewish community in the United States to press for greater funding for the American war effort, underway since April of that year; and, lastly, that it would undermine German Jewish support for Kaiser Wilhelm II. The declaration spurred an unintended and extraordinary increase in the number of adherents of American Zionism; in 1914 the 200 American Zionist societies comprised a total of 7,500 members, which grew to 30,000 members in 600 societies in 1918 and 149,000 members in 1919. Whilst the British had considered that the declaration reflected a previously established dominance of the Zionist position in Jewish thought, it was the declaration itself that was subsequently responsible for Zionism's legitimacy and leadership.
=== China (mainland) === The National Administration of Traditional Chinese Medicine was created in 1949, which then absorbed existing TCM management in 1986 with major changes in 1998. China's National People's Congress Standing Committee passed the country's first law on TCM in 2016, which came into effect on 1 July 2017. The new law standardized TCM certifications by requiring TCM practitioners to (i) pass exams administered by provincial-level TCM authorities, and (ii) obtain recommendations from two certified practitioners. TCM products and services can be advertised only with approval from the local TCM authority. Ready-to-use TCM preparations, also known as Chinese patent medicines, are regulated by the National Medical Products Administration (and its predecessor CFDA) similar to preparations used in modern medicine since 1984. The barrier for entry, however, is much lower than medications based on modern/non-TCM principles; the rules allow for omitting clinical testing in a variety of circumstances. As of 2025, the latest (2020) rules allow a simplified procedure for preparations derived from an approved list of "classic prescriptions". The government-run healthcare system covers a number of TCM procedures and preparations. In 2021, a total of 7114.5 billion yuan went into healthcare, amounting for 6.59% of the year's national GDP. Of these, 1111.5 billion yuan went into covering costs associated with TCM preparations (0.97% of national GDP), with 592.4 billion yuan covering the actual medications.
== History == In December 2008, the US Food and Drug Administration (FDA) approved degarelix for the treatment of people with advanced prostate cancer. It was subsequently approved by the European Commission at the recommendation of the European Medicines Agency (EMA) in February 2009, for use in adult males with advanced, hormone-dependent prostate cancer. Ferring Pharmaceuticals markets the drug under the name Firmagon.
Sources: en.wikipedia.org
==== Other actions ==== Bromantane has been found to increase the expression of neurotrophins including brain-derived neurotrophic factor and nerve growth factor in certain rat brain areas. Although not relevant at clinical dosages, bromantane has been found to produce anticholinergic effects, including both antimuscarinic and antinicotinic actions, at very high doses in animals, and these effects are responsible for its toxicity (that is, LD50) in animals.
Team Fortress 2 was nominated in the categories of "Outstanding Achievement in Art Direction" and "Outstanding Achievement in Animation" at the 11th Annual Interactive Achievement Awards. Although unsuccessful at the IAA, the game did receive 10 awards, including five Game of the Year awards, and other awards for its artistic direction and multiplayer gameplay. Half-Life 2: Episode Two won four awards, including one Game of the Year award, and was recognized for excellent NPC AI, level design, and story.
Diagnostic microbiology is the study of microbial identification. Since the discovery of the germ theory of disease, scientists have been finding ways to harvest specific organisms. Using methods such as differential media or genome sequencing, physicians and scientists can observe novel functions in organisms for more effective and accurate diagnosis of organisms. Methods used in diagnostic microbiology are often used to take advantage of a particular difference in organisms and attain information about what species it can be identified as, which is often through a reference of previous studies. New studies provide information that others can reference so that scientists can attain a basic understanding of the organism they are examining.
The first decision of the Socialist government of José Luis Rodríguez Zapatero was to order the withdrawal of Spanish troops from Iraq, thus fulfilling what was promised during the electoral campaign, which was accompanied by a rapprochement with Germany and France. This allowed the negotiations of the Treaty of the European Constitution, which was signed in Rome in October 2004, to be unblocked. Zapatero hastened to call the ratification referendum held in February 2005, which obtained the approval of 75% of the voters but registered the highest abstention of all democracy. However, Rodríguez Zapatero was isolated internationally when the European Constitution project foundered and, above all, when Germany and France "reconciled" with the United States. Moreover, his proposal for the Alliance of Civilizations presented to the 2004 UN General Assembly as an alternative to President Bush's "war on terror" found little international backing. The Popular Party blamed its defeat in the elections on the "manipulation" of public opinion during the two days following the "11-M" attack by the PSOE and the related media. Thus, the PP implicitly questioned the legitimacy of the new government and in the sessions of the parliamentary commission that was formed to investigate the events the PP spokesmen led by Eduardo Zaplana, endorsed the 11-M conspiracy theory.
"PDES" has generally applied to a wider scope, including, for example, virtual manufacturing techniques, while not necessarily integrating with laboratory equipment. In recent times LIMS functionality has spread even further beyond its original purpose of sample management. Assay data management, data mining, data analysis, and electronic laboratory notebook (ELN) integration have been added to many LIMS, enabling the realization of translational medicine completely within a single software solution. Additionally, the distinction between LIMS and LIS has blurred, as many LIMS now also fully support comprehensive case-centric clinical data.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.